VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms

Laboratory Investigation

Volumn 85, Issue 5, 2005, Pages 608-623

  Schoeffner, Daniel J ^a   Matheny, Shannon L ^a   Akahane, Takemi ^a   Factor, Valentina ^a   Berry, Adam ^a   Merlino, Glenn ^a   Thorgeirsson, Unnur P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Flk 1; Growth; Mammary; Middle T; Transgenic; VEGF

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOKINE; PROTEIN P16INK4A; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VIRUS MIDDLE T ANTIGEN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BREAST CARCINOGENESIS; BREAST EPITHELIUM; BREAST METASTASIS; BREAST TUMOR; CANCER INCIDENCE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; GENE EXPRESSION; GENE INACTIVATION; HUMAN; IN VITRO STUDY; LUNG METASTASIS; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN ANALYSIS; TRANSGENIC MOUSE; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BLOTTING, NORTHERN; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENES, P16; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 18744374621     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3700258     Document Type: Article

References (72)

1. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971;285:1182-1186.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
3. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med 1998;49:407-424.
4. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 1993;10:302-313.
5. Yoshiji H, Gomez DE, Shibuya M, et al. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 1996;56:2013-2016.
6. Obermair A, Kucera E, Mayerhofer K, et al. Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer 1997;74:455-458.
7. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985.
8. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-858.
9. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-1028.
10. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
11. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-745.
12. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-439.
13. Fong G-H, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66-70.
14. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-66.
15. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via VEGF receptor flt-1. Blood 1996;87:3336-3343.
16. Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 1999;19:5731-5740.
17. Gerber HP, Vu TH, Ryan AM, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5:623-628.
18. Suzuma K, Takagi H, Otani A, et al. Increased expression of KDR/Flk-1 (VEGFR-2) in murine model of ischemia-induced retinal neovascularization. Microvasc Res 1998;56:183-191.
19. Ishida A, Murray J, Saito Y, et al. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol 2001;188:359-368.
20. Kranz A, Mattfeldt T, Waltenberger J. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 1999;84:293-298.
21. Soker S, Kaefer M, Johnson M, et al. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 2001;159:651-659.
22. Tian X, Song S, Wu J, et al. Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun 2001;286:505-512.
23. Jackson MW, Roberts JS, Heckford SE, et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002;62:854-859.
24. Masood R, Cai J, Zheng T, et al. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA 1997;94:979-984.
25. Masood R, Cai J, Zheng T, et al. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001;98:1904-1913.
26. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-961.
27. Maglione JE, Moghanaki D, Young LJ, et al. Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 2001;61:8298-8305.
28. Huang AL, Ostrowski MC, Berard D, et al. Glucocorticoid regulation of the Ha-MuSV p21 gene conferred by sequences from mouse mammary tumor virus. Cell 1981;27:245-255.
29. Jhappan C, Stahle C, Harkins RN, et al. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 1990;61:1137-1146.
30. Kordon EC, McKnight RA, Jhappan C, et al. Ectopic TGF beta 1 expression in the secretory mammary epithelium induces early senescence of the epithelial stem cell population. Dev Biol 1995;168:47-61.
31. Berard J, Gaboury L, Landers M, et al. Hyperplasia and tumours in lung, breast and other tissues in mice carrying a RAR beta 4-like transgene. EMBO J 1994;13:5570-5580.
32. Tsukamoto AS, Grosschedl R, Guzman RC, et al. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1998;55:619-625.
33. Matsui Y, Halter SA, Holt JT, et al. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 1990;61:1147-1155.
34. Sinn E, Muller W, Pattengale P, et al. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 1987;49:465-475.
35. Leder A, Pattengale PK, Kuo A, et al. Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell 1986;45:485-495.
36. Korpelainen EI, Karkkainen MJ, Tenhunen A, et al. Overexpression of VEGF in testis and epididymis causes infertility in transgenic mice: evidence for nonendothelial targets for VEGF. J Cell Biol 1998;143:1705-1712.
37. Hennighausen L, Robinson GW. Think globally, act locally: the making of a mouse mammary gland. Genes Dev 1998;12:449-455.
38. Wagner K-U, Wall RJ, St-Onge L, et al. Cre-mediated dene deletion in the mammary gland. Nucelic Acid Res 1997;25:4323-4330.
39. Gerber H-P, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development 1999;126:1149-1159.
40. Keyt BA, Nguyen HV, Berleau LT, et al. Identification of vascular endothelial growth factor determinants for binding KDR and Flt-1 receptors. J Biol Chem 1996;271:5638-5646.
41. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-969.
42. Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor/vascular permeability factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997;57:3924-3928.
43. Nakopoulou L, Stefanaki K, Panayotopoulou E, et al. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol 2002;33:863-870.
44. Stewart M, Turley H, Cook N, et al. The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology 2003;43:33-39.
45. Bachelder RE, Crago A, Chung J, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001;61:5736-5740.
46. Kitsberg DI, Leder P. Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Oncogene 1996;13:2507-2515.
47. Krane IM, Leder P. DF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 1996;12:1781-1788.
48. Cardiff RD, Muller WJ. Transgenic mouse models of mammary tumorigenesis. Cancer Surv 1993;16:97-113.
49. Hennighausen L, Wall RJ, Tillmann U, et al. Conditional gene expression in secretory tissues and skin of transgenic mice using the MMTV-LTR and tetracycline responsive system. J Cell Biochem 1995;59:463-472.
50. Fukumura D, Gohongi T, Kadambi A, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 2001;98:2604-2609.
51. Yamashita T, Kawashima S, Ozaki M, et al. Role of endogenous nitric oxide generation in the regulation of vascular tone and reactivity in small vessels as investigated in transgenic mice using synchrotron radiation microangiography. Nitric Oxide 2001;5:494-503.
52. Harris SR, Schoeffher DJ, Yoshiji H, et al. Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Lett 2002;179:95-101.
53. Dvorak HF, Senger DR, Dvorak AM, et al: Regulation of extravascular coagulation by microvascular permeability. Science 1985;227:1059-1061.
54. Senger DR. Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Pathol 1996;149:1-7.
55. Brown LF, Guidi AJ, Schnitt SJ, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999;5:1041-1056.
56. McCarthy MJ, Crowther M, Bell PR, et al. The endothelial receptor tyrosine kinase tie-1 is upregulated by hypoxia and vascular endothelial growth factor. FEBS Lett 1998;423:334-338.
57. Oh H, Takagi H, Suzuma K, et al. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999;274:15732-15739.
58. Oh H, Takagi H, Otani A, et al. Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis. Proc Natl Acad Sci USA 2002;99:383-388.
59. Miao HQ, Lee P, Lin H, et al. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 2000;14:2532-2539.
60. Schorr K, Li M, Bar-Peled U, et al. Gain of Bcl-2 is more potent than bax loss in regulating mammary epithelial cell survival in vivo. Cancer Res 1999;59:2541-2560.
61. Shaheen RM, Tseng WW, Vellagas R, et al. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a mureine model of carcinomatosis. Int J Oncol 2001;18:221-226.
62. Muhlner U, Mohle-Steinlein U, Wizigmann-Voos S, et al. Formation of transformed endothelial cells in the absence of VEGFR-2/Flk-1 by polyoma middle T oncogene. Oncogene 1999;18:4200-4210.
63. Shi YP, Ferrara N. Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking vascular endothelial growth factor (VEGF). Biochem Biophys Res Commun 1999;254:480-483.
64. Macip S, Igarashi M, Fang L, et al. Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J 2002;21:2180-2188.
65. Yaswen P, Stampfer M. Molecular changes accompanying senescence and immortalization of cultured human mammary epithelial cells. Int J Biochem Cell Biol 2002;34:1382-1394.
66. Takeuchi H, Ozawa S, Shih CH, et al. Loss of p16INK4a expression is associated with vascular endothelial growth factor expression in squamous cell carcinoma of the esophagus. Int J Cancer 2004;109:483-490.
67. Kara da H, Nakagawa K, Iwata S, et al. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 1999;59:3783-3789.
68. Teruyama K, Abe M, Nakano T, et al. Role of transcription factor Ets-1 in the apoptosis of human vascular endothelial cells. J Cell Physiol 2001;188:243-252.
69. Senger DR, Ledbetter SR, Claffey KP, et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 1996;149:293-305.
70. Singhal H, Bautista DS, Tonkin KS, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997;3:605-611.
71. Esser S, Lampugnani MG, Corada M, et al. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 1998;111, (Part 13) 1853-1865.
72. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Eng J Med 2003;349:427-437.